OTCMKTS:RLMD - Relmada Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.90 0.00 (0.00 %)
(As of 08/20/2018 01:46 AM ET)
Previous Close$0.90
Today's Range$0.90 - $0.90
52-Week Range$0.61 - $1.94
Volume3,400 shs
Average Volume15,193 shs
Market Capitalization$15.30 million
P/E RatioN/A
Dividend YieldN/A
Beta0.12
Relmada Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases, primarily depression and chronic pain in the United States. Its lead product candidate, d-Methadone, is being developed as a rapidly acting, oral agent for the treatment of depression, neuropathic pain, and/or other potential CNS pathological conditions. The company is also developing LevoCap ER, an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol for the treatment of pain; BuTab ER, a formulation of oral, modified release buprenorphine for chronic pain and opioid dependence; and MepiGel, a proprietary topical dosage form of the local anesthetic mepivacaine for the treatment of painful peripheral neuropathies, such as painful diabetic neuropathy, postherpetic neuralgia, and painful HIV-associated neuropathy. Relmada Therapeutics, Inc. was founded in 2004 and is based in New York, New York.

Receive RLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:RLMD
CUSIPN/A
Phone212-547-9591

Debt

Debt-to-Equity Ratio-0.68
Current Ratio0.81
Quick Ratio0.81

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.12 per share
Price / Book7.50

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-6,280,000.00
Net MarginsN/A
Return on Equity-2,175.64%
Return on Assets-146.14%

Miscellaneous

Employees3
Outstanding Shares12,240,000
Market Cap$15.30 million

Relmada Therapeutics (OTCMKTS:RLMD) Frequently Asked Questions

What is Relmada Therapeutics' stock symbol?

Relmada Therapeutics trades on the OTCMKTS under the ticker symbol "RLMD."

When is Relmada Therapeutics' next earnings date?

Relmada Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, August, 20th 2018. View Earnings Estimates for Relmada Therapeutics.

Who are some of Relmada Therapeutics' key competitors?

Who are Relmada Therapeutics' key executives?

Relmada Therapeutics' management team includes the folowing people:
  • Dr. Sergio Traversa M.B.A., Pharm.D., PharmD, MBA, CEO, Interim CFO, Principal Accounting Officer & Director (Age 58)
  • Mr. Michael D. Becker, Consultant (Age 49)
  • Dr. Richard M. Mangano Ph.D., Consultant (Age 68)
  • Dr. Ottavio V. Vitolo, Sr. VP, Head of R&D & Chief Medical Officer (Age 45)
  • Dr. Fai Jim Ph.D., VP of Chemistry, Manufacturing and Controls

Has Relmada Therapeutics been receiving favorable news coverage?

Media headlines about RLMD stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Relmada Therapeutics earned a daily sentiment score of 0.16 on Accern's scale. They also gave news headlines about the company an impact score of 46.69 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Relmada Therapeutics.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Relmada Therapeutics' stock price today?

One share of RLMD stock can currently be purchased for approximately $0.90.

How big of a company is Relmada Therapeutics?

Relmada Therapeutics has a market capitalization of $15.30 million. Relmada Therapeutics employs 3 workers across the globe.

How can I contact Relmada Therapeutics?

Relmada Therapeutics' mailing address is 750 Third Avenue 9th Floor, NEW YORK NY, 10017. The company can be reached via phone at 212-547-9591 or via email at [email protected]


MarketBeat Community Rating for Relmada Therapeutics (OTCMKTS RLMD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  62 (Vote Underperform)
Total Votes:  130
MarketBeat's community ratings are surveys of what our community members think about Relmada Therapeutics and other stocks. Vote "Outperform" if you believe RLMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel